SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------------
FORM 8-K/A
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of event reported):
DECEMBER 20, 1999
GENOME THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 0-10824 04-2297484
(State or other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
100 BEAVER STREET, WALTHAM, MASSACHUSETTS 02453
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code:
(781) 398-2300
ITEM 5.
On December 20, 1999, Genome Therapeutics Corporation entered into a
collaboration and license agreement with American Home Products Corporation.
This current report on Form 8-K is filed solely to file such agreement to
disclose portions of the agreement that were previously redacted.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(a) Financial Statements of Business Acquired.
Not applicable.
(b) PRO FORMA Financial Information.
Not applicable.
(c) Exhibits
10.1* Collaboration and License Agreement between Genome
Therapeutics Corporation, and American Home Products
Corporation dated as of December 20, 1999. Filed
herewith.
* Certain confidential material contained in the document has been omitted
and filed separately with the SEC pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
April 10, 2000 GENOME THERAPEUTICS CORP.
By: /S/ PHILIP V HOLBERTON
---------------------------------
Philip V. Holberton
Chief Financial Officer
3
EXHIBIT INDEX
10.1* Collaboration and License Agreement between Genome
Therapeutics Corporation, and American Home Products
Corporation dated as of December 20, 1999. Filed
herewith.
* Certain confidential material contained in the document has been
omitted and filed separately with the SEC pursuant to Rule 24b-2 of the
Securities Exchange Act of 1934.
4